HK1203975A1 - Genetically modified human natural killer cell lines - Google Patents
Genetically modified human natural killer cell linesInfo
- Publication number
- HK1203975A1 HK1203975A1 HK15104418.9A HK15104418A HK1203975A1 HK 1203975 A1 HK1203975 A1 HK 1203975A1 HK 15104418 A HK15104418 A HK 15104418A HK 1203975 A1 HK1203975 A1 HK 1203975A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- natural killer
- killer cell
- cell lines
- genetically modified
- modified
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 3
- 108010087819 Fc receptors Proteins 0.000 abstract 2
- 102000009109 Fc receptors Human genes 0.000 abstract 2
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 108010002350 Interleukin-2 Proteins 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 abstract 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 abstract 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000034285 signal transducing proteins Human genes 0.000 abstract 1
- 108091006024 signal transducing proteins Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58658104P | 2004-07-10 | 2004-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1203975A1 true HK1203975A1 (en) | 2015-11-06 |
Family
ID=35968029
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104418.9A HK1203975A1 (en) | 2004-07-10 | 2015-05-11 | Genetically modified human natural killer cell lines |
HK16103322.5A HK1215269A1 (zh) | 2004-07-10 | 2016-03-22 | 基因修飾的人自然殺傷細胞系 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16103322.5A HK1215269A1 (zh) | 2004-07-10 | 2016-03-22 | 基因修飾的人自然殺傷細胞系 |
Country Status (12)
Country | Link |
---|---|
US (8) | US7618817B2 (da) |
EP (5) | EP2921500B1 (da) |
AT (1) | ATE443084T1 (da) |
AU (1) | AU2005277831B2 (da) |
CA (2) | CA3052445C (da) |
DE (1) | DE602005016683D1 (da) |
DK (4) | DK2112162T3 (da) |
ES (3) | ES2678094T3 (da) |
HK (2) | HK1203975A1 (da) |
PL (1) | PL2921500T3 (da) |
PT (1) | PT2921500T (da) |
WO (1) | WO2006023148A2 (da) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3052445C (en) | 2004-07-10 | 2023-08-22 | Kerry S. Campbell | Genetically modified human natural killer cell lines |
US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
MX2009002414A (es) | 2006-09-08 | 2009-05-20 | Medimmune Llc | Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria. |
EP2703011A3 (en) | 2007-05-07 | 2014-03-26 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
JP5282040B2 (ja) * | 2007-09-28 | 2013-09-04 | オリンパス株式会社 | Fc受容体遺伝子導入NK細胞を用いた抗体依存性細胞傷害のアッセイ方法 |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
KR101759457B1 (ko) | 2007-12-21 | 2017-07-31 | 메디뮨 리미티드 | 인터루킨-4 수용체 알파(IL-4Rα)에 대한 결합 구성원-173 |
EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン,エルエルシー | 抗体製剤 |
WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
EP2847223B1 (en) | 2012-05-07 | 2019-03-27 | Trustees of Dartmouth College | Anti-b7-h6 antibody, fusion proteins, and methods of using the same |
RU2683498C2 (ru) | 2013-10-02 | 2019-03-28 | МЕДИММЬЮН, ЭлЭлСи | Нейтрализующие антитела к вирусу гриппа а и пути их применения |
KR102329796B1 (ko) | 2013-11-01 | 2021-11-23 | 이뮤너티바이오, 인크. | 종양세포 치사활성 및 항균성 조성물 및 방법 |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
WO2015148926A1 (en) | 2014-03-28 | 2015-10-01 | Regents Of The University Of Minnesota | Polypeptides, cells, and methods involving engineered cd16 |
JP6694875B2 (ja) | 2014-05-15 | 2020-05-20 | ナショナル ユニヴァーシティ オブ シンガポール | 改変ナチュラルキラー細胞及びその使用 |
US20170182292A1 (en) | 2014-05-22 | 2017-06-29 | Nantkwest, Inc. | Treating solid tumours with nk-92 cells applied by microcatheter |
US20170151283A1 (en) * | 2014-05-23 | 2017-06-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating antibody resistance |
WO2015193411A1 (en) | 2014-06-18 | 2015-12-23 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Car-expressing nk-92 cells as cell therapeutic agents |
ES2942485T3 (es) * | 2014-10-06 | 2023-06-01 | Immunitybio Inc | Tratamiento de la fiebre hemorrágica vírica con células NK-92 |
GB201501175D0 (en) * | 2015-01-23 | 2015-03-11 | Univ Oslo Hf | A universal T-cell for personalised medicine |
KR20170131562A (ko) * | 2015-03-27 | 2017-11-29 | 난트케이웨스트, 인크. | 암 약물과의 조합 요법에서의 nk-92 세포 |
IL287051B (en) * | 2015-03-27 | 2022-09-01 | Immunitybio Inc | nk-2 cells and genetically engineered monoclonal antibodies for cancer treatment |
JP2018513201A (ja) | 2015-04-25 | 2018-05-24 | ザ ジェネラル ホスピタル コーポレイション | 抗fugetactic剤と抗癌剤の併用療法、および、癌の治療のための組成物 |
SI3303384T1 (sl) | 2015-06-01 | 2021-11-30 | Medimmune Llc | Nevtralizirajoče vezavne molekule proti-influenci in njihova uporaba |
IL309167A (en) * | 2015-06-10 | 2024-02-01 | Immunitybio Inc | Modified NK-92 cells for cancer treatment |
AU2016300128B2 (en) | 2015-07-29 | 2022-03-17 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
EP3349797A4 (en) | 2015-09-18 | 2019-06-12 | The General Hospital Corporation Dba Massachusetts General Hospital | LOCALIZED DELIVERY OF ANTICHIMIOREPULSION AGENT FOR THE TREATMENT OF CANCER |
US10533157B1 (en) | 2015-12-03 | 2020-01-14 | Nantbio, Inc. | Recombinant NK cells expressing co-stimulatory molecules |
EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | INTERFERON CANCER TREATMENT METHODS |
US10973852B2 (en) | 2016-01-25 | 2021-04-13 | Nantcell, Inc. | NK cells with altered CXCL12/CXCR4 signaling |
WO2017184534A1 (en) * | 2016-04-18 | 2017-10-26 | The Gorlin Companies | Methods and compositions for improving safety and efficacy of natural killer cell immunotherapy |
US20200316118A1 (en) | 2016-05-19 | 2020-10-08 | The General Hospital Corporation | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
US11419894B2 (en) * | 2016-09-16 | 2022-08-23 | The General Hospital Corporation | Modified natural killer cells for the treatment of cancer |
CA3036713A1 (en) | 2016-09-29 | 2018-04-05 | Nantkwest, Inc. | Hla class i-deficient nk-92 cells with decreased immunogenicity |
US11752172B2 (en) | 2017-01-04 | 2023-09-12 | Nova Southeastern University | Natural killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex, methods for production thereof, and methods for therapeutic use thereof |
JP7118072B2 (ja) | 2017-01-06 | 2022-08-15 | イミュニティーバイオ インコーポレイテッド | Cd96/tigit発現が低下した遺伝子改変型nk-92細胞 |
AU2018214558B2 (en) * | 2017-02-01 | 2020-08-27 | Immunitybio, Inc. | Calreticulin-mediated cancer treatment |
WO2018148224A1 (en) | 2017-02-07 | 2018-08-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Phospholipid ether (ple) car t cell tumor targeting (ctct) agents |
CN110546265A (zh) * | 2017-02-09 | 2019-12-06 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞及其组合物和方法 |
EP3589295A4 (en) | 2017-02-28 | 2020-11-04 | Endocyte, Inc. | COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY |
AU2018231193B2 (en) * | 2017-03-08 | 2021-07-22 | Immunitybio, Inc. | Modified NK-92 haNK003 cells for the clinic |
EP3600395A4 (en) | 2017-03-23 | 2021-05-05 | The General Hospital Corporation | BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE |
JP2020511981A (ja) * | 2017-03-27 | 2020-04-23 | ナントセル,インコーポレイテッド | aNK及びIL−12組成物及び方法 |
KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
JP7270253B2 (ja) | 2017-03-27 | 2023-05-10 | ナショナル ユニヴァーシティ オブ シンガポール | ナチュラルキラー細胞のエクスビボ拡大及び活性化のための刺激細胞株 |
AU2018311096A1 (en) | 2017-08-04 | 2020-01-30 | Nantkwest, Inc. | Treating and inhibiting leukemia with NK-92 cells |
JP2021500923A (ja) * | 2017-10-26 | 2021-01-14 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 組換え免疫細胞、作製方法、および使用方法 |
WO2019084284A1 (en) | 2017-10-27 | 2019-05-02 | Coneksis, Inc. | NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS |
EP3703735A1 (en) | 2017-11-01 | 2020-09-09 | Nantkwest, Inc. | Nk-92 cells to stimulate anti-cancer vaccine |
JP2021512147A (ja) | 2018-01-22 | 2021-05-13 | エンドサイト・インコーポレイテッドEndocyte, Inc. | Car t細胞の使用方法 |
WO2019152513A1 (en) | 2018-01-31 | 2019-08-08 | Nantkwest, Inc. | Use of 5% human albumin in wash and harvest media |
WO2019177986A1 (en) | 2018-03-12 | 2019-09-19 | Nantkwest, Inc. | Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity) |
US20190321402A1 (en) * | 2018-04-19 | 2019-10-24 | Onkimmune Limited | Nk cells for use with anitbodies in cancer therapy |
US20210187025A1 (en) * | 2018-05-14 | 2021-06-24 | Indapta Therapeutics, Inc. | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
AU2019274392A1 (en) | 2018-05-22 | 2020-11-05 | Nantkwest, Inc. | Basal media for growing NK-92 cells |
EP3797149A1 (en) | 2018-05-22 | 2021-03-31 | Nantkwest, Inc. | Methods and systems for cell bed formation during bioprocessing |
US20210198342A1 (en) * | 2018-05-22 | 2021-07-01 | Nantkwest, Inc. | FC-EPSILON CAR (Very imp commercially - in clinical trial) |
JP7208262B2 (ja) | 2018-05-22 | 2023-01-18 | イミュニティーバイオ インコーポレイテッド | ポロキサマーを用いてnk-92細胞増殖を最適化する方法 |
WO2020014245A1 (en) | 2018-07-10 | 2020-01-16 | Nantkwest, Inc. | Cryopreservation |
CN113164519A (zh) | 2018-08-01 | 2021-07-23 | 南克维斯特公司 | 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统 |
WO2020028654A1 (en) | 2018-08-01 | 2020-02-06 | Nantkwest, Inc. | Combined invasion and cytotoxicity assay using chemokine secreting target cells |
EP3743512A4 (en) | 2018-10-31 | 2021-12-01 | Nantkwest, Inc. | ELIMINATION OF CD19 POSITIVE LYMPHOID MALIGNACIES BY NK CELLS EXPRESSING CD19-CAR |
JP7092404B2 (ja) * | 2018-10-31 | 2022-06-28 | イミュニティーバイオ、インコーポレイテッド | Pd-l1キメラ抗原受容体を発現するnk細胞によるpd-l1陽性悪性腫瘍の排除 |
CN112352048A (zh) | 2018-11-06 | 2021-02-09 | 南克维斯特公司 | 嵌合抗原受体修饰的nk-92细胞 |
US20220017594A1 (en) | 2018-11-26 | 2022-01-20 | Nantkwest, Inc. | Il-2 dependent nk-92 cells with stable fc receptor expression |
EP3898701A4 (en) * | 2018-12-20 | 2022-10-26 | Kleo Pharmaceuticals, Inc. | POLYTHERAPY ARMS CELLS AND NATURAL KILLER CELLS |
CA3125503A1 (en) * | 2019-01-18 | 2020-07-23 | Acepodia Biotechnologies Ltd. | A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell |
CA3133037A1 (en) * | 2019-03-19 | 2020-09-24 | Ramot At Tel-Aviv University Ltd. | T cell expressing an fc gamma receptor and methods of use thereof |
JP2022526504A (ja) | 2019-03-21 | 2022-05-25 | オーエヌケー セラピューティクス リミテッド | 細胞死に対する耐性が増大した改変免疫エフェクター細胞 |
EP3712257A1 (en) | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modified natural killer cells with increased resistance to cell death |
AU2020261039A1 (en) | 2019-04-23 | 2021-12-09 | Sanofi | Anti-CD38 antibodies and formulations |
US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
US20220144952A1 (en) * | 2019-08-01 | 2022-05-12 | Nantkwest, Inc. | Anti-B7-H4 Chimeric Antigen Receptor-Modified NK-92 Cells |
CA3149810A1 (en) | 2019-08-15 | 2021-02-18 | Nantbio, Inc. | Tgf-beta trap |
WO2021101467A1 (en) * | 2019-11-19 | 2021-05-27 | Acibadem Mehmet Ali̇ Aydinlar Üni̇versi̇tesi̇ | A method for redesign and expansion of nk92 cells for use in immunotherapy |
CN115190910A (zh) | 2019-11-20 | 2022-10-14 | 免疫生物公司 | 细胞介导的免疫增强分子到肿瘤微环境中的瞬时递送 |
CN113646435A (zh) * | 2019-12-09 | 2021-11-12 | 南克维斯特公司 | 通过非抗生素依赖性阳性选择筛选表达多基因转基因的细胞克隆 |
US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
WO2021154218A1 (en) * | 2020-01-28 | 2021-08-05 | Nantkwest, Inc. | Chimeric antigen receptor-modified nk-92 cells targeting egfr super-family receptors |
US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
CN113603787B (zh) * | 2020-05-04 | 2023-05-23 | 英诺康生物医药科技(广州)有限公司 | 一种非分泌型的人白细胞介素15及应用 |
TW202216771A (zh) | 2020-06-26 | 2022-05-01 | 德商拜耳廠股份有限公司 | 用於治療應用之ccr8抗體 |
US20220401485A1 (en) * | 2020-08-11 | 2022-12-22 | Immunitybio, Inc. | Chimeric Antigen Receptor-Modified NK-92 Cells |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
AU2021401052A1 (en) | 2020-12-18 | 2023-06-22 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
WO2022153212A1 (en) | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
EP4108247A1 (en) | 2021-06-23 | 2022-12-28 | Ostravska univerzita | Urine progenitor cells for use in cancer therapy |
WO2023081163A1 (en) | 2021-11-02 | 2023-05-11 | Immunitybio, Inc. | Natural killer cells for chordoma therapy |
EP4180049A1 (en) | 2021-11-16 | 2023-05-17 | Ostravska univerzita | Therapeutic composition for cancer treatment |
WO2023114901A2 (en) * | 2021-12-15 | 2023-06-22 | Oxford Biomedica Solutions Llc | Methods and compositions for the production of adeno-associated virus |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3733919A (en) * | 1971-09-20 | 1973-05-22 | Adjustable eccentric bearing mountings background | |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5767077A (en) | 1988-05-27 | 1998-06-16 | Applied Research Systems Ars Holding N.V. | Human Fc-γ receptor III |
JP2657221B2 (ja) | 1988-05-27 | 1997-09-24 | アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ | ヒトFcγレセプター▲III▼ |
CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
US7038031B1 (en) | 1989-07-28 | 2006-05-02 | Sloan-Kettering Institute For Cancer Research | DNA encoding FcγR receptor protein on NK cells |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
CA2188422C (en) | 1994-05-02 | 2011-03-15 | Bernd Groner | Bifunctional protein, preparation and use |
KR100343214B1 (ko) * | 1995-03-28 | 2002-11-13 | 삼성에스디아이 주식회사 | 전계방출소자의제조방법 |
US5830725A (en) | 1995-04-28 | 1998-11-03 | The Board Of Trustees For The Leland Stanford Junior University | Rapid, stable high-titre production of recombing retrovirus |
AU2582897A (en) | 1996-03-15 | 1997-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
DE69834257T2 (de) | 1997-04-30 | 2007-01-04 | Klingemann, Hans | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
US20030026780A1 (en) * | 2001-07-18 | 2003-02-06 | Hood Leroy E. | Innate immunity mediated methods of treating pathological conditions |
CA2481925A1 (en) * | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
US7618617B2 (en) * | 2002-05-31 | 2009-11-17 | L'oreal | Aqueous hair treatment compositions, thickened with an amphiphilic linear block copolymer |
MXPA05013923A (es) | 2003-07-02 | 2006-08-11 | Univ Genova | Anticuerpos nk receptores de pan-kir2dl y su utilizacion en diagnostico y terapia. |
AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
CA3052445C (en) * | 2004-07-10 | 2023-08-22 | Kerry S. Campbell | Genetically modified human natural killer cell lines |
ATE531733T1 (de) | 2005-01-06 | 2011-11-15 | Novo Nordisk As | Kir-bindende wirkstoffe und verfahren zu ihrer verwendung |
-
2005
- 2005-07-08 CA CA3052445A patent/CA3052445C/en active Active
- 2005-07-08 EP EP15150984.1A patent/EP2921500B1/en active Active
- 2005-07-08 AT AT05789289T patent/ATE443084T1/de not_active IP Right Cessation
- 2005-07-08 ES ES14171739.7T patent/ES2678094T3/es active Active
- 2005-07-08 ES ES15150984T patent/ES2955952T3/es active Active
- 2005-07-08 AU AU2005277831A patent/AU2005277831B2/en active Active
- 2005-07-08 PT PT151509841T patent/PT2921500T/pt unknown
- 2005-07-08 CA CA2572938A patent/CA2572938C/en active Active
- 2005-07-08 WO PCT/US2005/024229 patent/WO2006023148A2/en active Application Filing
- 2005-07-08 EP EP18169049.6A patent/EP3406631B1/en active Active
- 2005-07-08 PL PL15150984.1T patent/PL2921500T3/pl unknown
- 2005-07-08 DK DK09164804T patent/DK2112162T3/da active
- 2005-07-08 DK DK14171739.7T patent/DK2801583T3/da active
- 2005-07-08 EP EP20050789289 patent/EP1771471B1/en not_active Revoked
- 2005-07-08 EP EP20090164804 patent/EP2112162B1/en active Active
- 2005-07-08 DK DK15150984.1T patent/DK2921500T3/da active
- 2005-07-08 ES ES18169049T patent/ES2925912T3/es active Active
- 2005-07-08 DK DK18169049.6T patent/DK3406631T3/da active
- 2005-07-08 US US11/178,258 patent/US7618817B2/en active Active
- 2005-07-08 EP EP14171739.7A patent/EP2801583B1/en active Active
- 2005-07-08 DE DE200560016683 patent/DE602005016683D1/de active Active
-
2008
- 2008-04-21 US US12/106,665 patent/US20080247990A1/en not_active Abandoned
-
2009
- 2009-09-22 US US12/564,255 patent/US9150636B2/en active Active
- 2009-09-22 US US12/564,283 patent/US8313943B2/en active Active
-
2012
- 2012-10-15 US US13/651,797 patent/US9181322B2/en active Active
-
2015
- 2015-05-11 HK HK15104418.9A patent/HK1203975A1/xx unknown
- 2015-08-26 US US14/836,927 patent/US20160067356A1/en not_active Abandoned
-
2016
- 2016-03-22 HK HK16103322.5A patent/HK1215269A1/zh unknown
-
2022
- 2022-10-27 US US18/050,216 patent/US20230372545A1/en active Pending
-
2023
- 2023-07-25 US US18/358,738 patent/US20240016957A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1215269A1 (zh) | 基因修飾的人自然殺傷細胞系 | |
WO2005007121A3 (en) | Mutant interleukin-2(il-2) polypeptides | |
DK1639013T3 (da) | Pan-kir2dl-nk-receptor-antistoffer og anvendelse heraf til diagnosticering og terapi | |
IL186986A0 (en) | Compositions and methods for modulating immune responses | |
WO2008033403A3 (en) | Agents and methods to elicit anti-tumor immune response | |
DK1645626T3 (da) | Cellelinie | |
AU2005211385A1 (en) | Modified human growth hormone polypeptides and their uses | |
GB0304068D0 (en) | Substances | |
ATE475669T1 (de) | Einen modifizierten t-zellen-rezeptor exprimierende zellen | |
GB0713656D0 (en) | Modified human growth hormone | |
WO2006029010A3 (en) | Methods of activating nkt cells | |
ATE389670T1 (de) | Selektive peptidische agonisten des vpac2- rezeptors | |
EP1677643A4 (en) | APPARATUS FOR FIXING ARTIFICIAL NAIL | |
GT200300199A (es) | Indoles 2,7-sustituidos | |
CA2466778A1 (en) | Flexible seat mount for chair seat bottom | |
AU2002364302A1 (en) | Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases | |
ATE412010T1 (de) | Selektive peptidische agonisten des vpac2- rezeptors | |
WO2005001042A8 (en) | Smooth muscle progenitor cells | |
GR3022080T3 (en) | T-cell receptor gene located within alpha locus and dna constructions | |
GB2430136A (en) | Personal accessory carrier | |
DE602004013291D1 (de) | Dendritische zelle mit alpha-glycosylceramid-derivat und antigen zur verwendung bei der unterdrückung von immunreaktionen | |
ATE450773T1 (de) | Aufnahme für taktische ausrüstung mit zubehörbefestigungsschiene | |
Grosholz et al. | OOS 18-4: The importance of propagule source region as a component of propagule pressure for marine invasions | |
HUP0301680A2 (hu) | Alul nyitott pontonok | |
TR200402060U (tr) | Güneş şemsiyesinin sabitlenmesi için su doldurulabilen bidon. |